Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77

Benzinga Newsdesk www.benzinga.com Negative 74.4%

Neg 74.4% Neu 0% Pos 0%

Barclays analyst Etzer Darout downgrades Forte Biosciences (NASDAQ:FBRX) from Overweight to Equal-Weight and raises the price target from $74 to $77.